European Institute of Oncology / Istituto Europeo di Oncologia (IEO)

Research / Science organisation


Location: Milano / Mailand, Italy (IT) IT

ISNI: 0000000417570843

ROR: https://ror.org/02vr0ne26

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Relationship Between Metabolic Toxicity and Efficacy of Everolimus in Patients With Neuroendocrine Tumors (NETs): A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials (2019) Fazio N, Carnaghi C, Valle JW, Herbst F, Ridolfi A, Strosberg J, Kulke MH, et al. Conference contribution Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA (2019) Janssens R, Russo S, van Overbeeke E, Whichello C, Harding S, Kübler J, Juhaeri J, et al. Journal article A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB) (2019) Mayer IA, Prat A, Egle D, Blau S, Alejandro Perez Fidalgo J, Gnant M, Fasching P, et al. Journal article Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial (2019) Denkert C, Budczies J, Regan MM, Loibl S, Dell’Orto P, von Minckwitz G, Mastropasqua MG, et al. Journal article Unmet medical needs in metastatic lung and digestive neuroendocrine neoplasms (2019) Capdevila J, Bodei L, Davies P, Gorbounova V, Jensen RT, Knigge UP, Krejs GJ, et al. Journal article Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) (2018) Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, Li D, et al. Conference contribution mHealth and telemedicine apps: in search of a common regulation (2018) Crico C, Renzi C, Graf N, Buyx A, Kondylakis H, Koumakis L, Pravettoni G Journal article The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity (2018) Colombo M, Lopez-Perolio I, Meeks HD, Caleca L, Parsons MT, Li H, De Vecchi G, et al. Journal article Development and validation of the SIMPLE endoscopic classification of diminutive and small colorectal polyps (2018) Iacucci M, Trovato C, Daperno M, Akinola O, Greenwald D, Gross SA, Hoffman A, et al. Journal article Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution
‹ 1 ... 3 4 5 6 7 8 ›